Figs Shares Surge 23.9% Following Strong Quarterly Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2026
0mins
Source: Fool
- Quarterly Revenue Surge: Figs reported a 33% year-over-year increase in fourth-quarter revenue, reaching $201.9 million, highlighting strong demand in the healthcare apparel market and solidifying its market position.
- Sales Breakdown Performance: Scrubwear sales jumped 35.1% to $154.9 million, while non-scrubwear sales rose 26.4% to $47 million, indicating the success of the company's diversified product strategy.
- International Market Expansion: Figs' international revenue soared 55.1% to $37.7 million, reflecting the effectiveness of its global expansion strategy, which is expected to drive future growth.
- Optimistic Future Outlook: Figs anticipates full-year revenue growth of 10% to 12% for 2026 and plans to increase its adjusted EBITDA margin from 11.8% in 2025 to 12.8%, demonstrating confidence in its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FIGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FIGS
Wall Street analysts forecast FIGS stock price to fall
5 Analyst Rating
2 Buy
2 Hold
1 Sell
Hold
Current: 15.470
Low
7.50
Averages
10.70
High
15.00
Current: 15.470
Low
7.50
Averages
10.70
High
15.00
About FIGS
FIGS, Inc. operates as a direct-to-consumer healthcare apparel and lifestyle brand. The Company sells products designed to serve the particular needs of healthcare professionals primarily through its direct-to-consumer (DTC) digital platform, consisting of its Website, mobile app and B2B business (TEAMS). Its offerings include scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and other apparel. Its non-scrubwear products are designed as an integrated system that complements its scrubwear and are comprised of base layer and outer layer products. Its underscrubs include sports bras, performance leggings, performance tops and super-soft pima cotton tops. Its under underscrubs include several styles of underwear. Its outer layer products include footwear, lab coats, and a variety of vests, jackets, and fleeces. The Company also offers necessities, such as scrub caps, lanyards, badge reels, tote bags, baseball caps, and beanies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street's Affection for FIGS: What Do Price Targets Indicate About a Potential Decline?
Stock Performance: Following a significant recovery, FIGS, Inc. has seen its stock surge nearly 260% over the past year, currently trading above $17, despite a consensus 12-month price target of $12.25, indicating skepticism about its valuation.
Earnings Momentum: The company reported strong earnings growth, with Q3 2025 results exceeding expectations, leading to a stock rally of over 30% and prompting analysts to upgrade their ratings, reflecting confidence in FIGS' future prospects.
Market Challenges: Despite positive earnings, analysts express caution regarding the stock's valuation, noting that it trades at a high price-to-earnings ratio, suggesting that much of the expected growth may already be priced in.
Future Outlook: FIGS anticipates continued revenue growth of 10% to 12% for fiscal 2026, driven by strong demand in the healthcare sector, while also planning to expand into new international markets and maintain its stock buyback program.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Figs Shares Surge 23.9% Following Strong Quarterly Performance
- Quarterly Revenue Surge: Figs reported a 33% year-over-year increase in fourth-quarter revenue, reaching $201.9 million, highlighting strong demand in the healthcare apparel market and solidifying its market position.
- Sales Breakdown Performance: Scrubwear sales jumped 35.1% to $154.9 million, while non-scrubwear sales rose 26.4% to $47 million, indicating the success of the company's diversified product strategy.
- International Market Expansion: Figs' international revenue soared 55.1% to $37.7 million, reflecting the effectiveness of its global expansion strategy, which is expected to drive future growth.
- Optimistic Future Outlook: Figs anticipates full-year revenue growth of 10% to 12% for 2026 and plans to increase its adjusted EBITDA margin from 11.8% in 2025 to 12.8%, demonstrating confidence in its future performance.
See More
Figs Reports Strong Sales Growth, Shares Rise 23%
- Significant Sales Growth: Figs' fourth-quarter revenue surged 33% year-over-year to $201.9 million, with Scrubwear sales jumping 35.1% to $154.9 million and non-scrubwear sales increasing 26.4% to $47 million, indicating strong demand in the healthcare apparel market.
- Strong Regional Performance: U.S. revenue rose 28.7% to $164.2 million, while international revenue soared 55.1% to $37.7 million, demonstrating Figs' rapidly increasing market penetration among healthcare professionals globally.
- Improved Profitability: Figs' EBITDA climbed 26.8% to $26.7 million, with projections for an adjusted EBITDA margin of 12.8% in 2026, up from 11.8% in 2025, reflecting ongoing enhancements in the company's profitability.
- Optimistic Investment Outlook: Analysts at KeyBanc set a $17 price target for Figs' shares, indicating a potential 10% return from Friday's closing price, showcasing market confidence in the company's future growth prospects.
See More
FIGS Inc Surpasses Q4 Expectations with Strong Earnings
- Strong Earnings Growth: FIGS Inc reported earnings of $0.10 per share for Q4, significantly exceeding the analyst estimate of $0.02 and improving from $0.01 a year earlier, indicating a substantial enhancement in profitability.
- Outstanding Revenue Performance: The company achieved revenue of $201.9 million, surpassing market expectations by over 22% and marking a 33% year-over-year increase, demonstrating broad-based growth across all business segments.
- Significant Net Income Increase: FIGS' net income rose to $18.5 million from $1.9 million a year prior, lifting the net income margin to 9.2%, reflecting successful operational efficiency and cost management.
- Positive Future Outlook: FIGS anticipates revenue growth of 10% to 12% year-over-year for 2026, with adjusted EBITDA margins projected between 12.7% and 12.9%, highlighting the company's long-term growth potential in serving healthcare professionals globally.
See More
Key Wall Street Calls on Friday: Upgrades and Downgrades
- Core Stock Rating: Deutsche Bank reiterates its Buy rating on CoreWeave, lowering the price target from $140 to $125, indicating that the company faces uncertainties in its rapidly scaling financial model, which may impact investor confidence.
- Strong Airline Demand: TD Cowen upgrades Southwest Airlines from Hold to Buy with a target price of $66, anticipating strengthened airline demand in 2026, reflecting the potential for industry recovery.
- AI Software Leader: Rosenblatt initiates coverage of Palantir with a Buy rating and a $150 price target, believing the company holds a unique market position in AI with a sustainable growth trajectory, despite a 33% decline from its peak.
- Optimistic Financial Performance: Bank of America raises Dell's price target to $155, based on its broad product portfolio and AI-related growth potential, expecting higher margins in the coming years, although global economic slowdown poses some risks.
See More
Wall Street's Affection for FIGS: What Do Price Targets Indicate About a Potential Decline?
Stock Performance: Following a significant recovery, FIGS, Inc. has seen its stock surge nearly 260% over the past year, currently trading above $17, despite a consensus 12-month price target of $12.25, indicating skepticism about its valuation.
Earnings Momentum: The company reported strong earnings growth, with Q3 2025 results exceeding expectations, leading to a stock rally of over 30% and prompting analysts to upgrade their ratings, reflecting confidence in FIGS' future prospects.
Market Challenges: Despite positive earnings, analysts express caution regarding the stock's valuation, noting that it trades at a high price-to-earnings ratio, suggesting that much of the expected growth may already be priced in.
Future Outlook: FIGS anticipates continued revenue growth of 10% to 12% for fiscal 2026, driven by strong demand in the healthcare sector, while also planning to expand into new international markets and maintain its stock buyback program.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Figs Shares Surge 23.9% Following Strong Quarterly Performance
- Quarterly Revenue Surge: Figs reported a 33% year-over-year increase in fourth-quarter revenue, reaching $201.9 million, highlighting strong demand in the healthcare apparel market and solidifying its market position.
- Sales Breakdown Performance: Scrubwear sales jumped 35.1% to $154.9 million, while non-scrubwear sales rose 26.4% to $47 million, indicating the success of the company's diversified product strategy.
- International Market Expansion: Figs' international revenue soared 55.1% to $37.7 million, reflecting the effectiveness of its global expansion strategy, which is expected to drive future growth.
- Optimistic Future Outlook: Figs anticipates full-year revenue growth of 10% to 12% for 2026 and plans to increase its adjusted EBITDA margin from 11.8% in 2025 to 12.8%, demonstrating confidence in its future performance.
See More
Figs Reports Strong Sales Growth, Shares Rise 23%
- Significant Sales Growth: Figs' fourth-quarter revenue surged 33% year-over-year to $201.9 million, with Scrubwear sales jumping 35.1% to $154.9 million and non-scrubwear sales increasing 26.4% to $47 million, indicating strong demand in the healthcare apparel market.
- Strong Regional Performance: U.S. revenue rose 28.7% to $164.2 million, while international revenue soared 55.1% to $37.7 million, demonstrating Figs' rapidly increasing market penetration among healthcare professionals globally.
- Improved Profitability: Figs' EBITDA climbed 26.8% to $26.7 million, with projections for an adjusted EBITDA margin of 12.8% in 2026, up from 11.8% in 2025, reflecting ongoing enhancements in the company's profitability.
- Optimistic Investment Outlook: Analysts at KeyBanc set a $17 price target for Figs' shares, indicating a potential 10% return from Friday's closing price, showcasing market confidence in the company's future growth prospects.
See More
FIGS Inc Surpasses Q4 Expectations with Strong Earnings
- Strong Earnings Growth: FIGS Inc reported earnings of $0.10 per share for Q4, significantly exceeding the analyst estimate of $0.02 and improving from $0.01 a year earlier, indicating a substantial enhancement in profitability.
- Outstanding Revenue Performance: The company achieved revenue of $201.9 million, surpassing market expectations by over 22% and marking a 33% year-over-year increase, demonstrating broad-based growth across all business segments.
- Significant Net Income Increase: FIGS' net income rose to $18.5 million from $1.9 million a year prior, lifting the net income margin to 9.2%, reflecting successful operational efficiency and cost management.
- Positive Future Outlook: FIGS anticipates revenue growth of 10% to 12% year-over-year for 2026, with adjusted EBITDA margins projected between 12.7% and 12.9%, highlighting the company's long-term growth potential in serving healthcare professionals globally.
See More
Key Wall Street Calls on Friday: Upgrades and Downgrades
- Core Stock Rating: Deutsche Bank reiterates its Buy rating on CoreWeave, lowering the price target from $140 to $125, indicating that the company faces uncertainties in its rapidly scaling financial model, which may impact investor confidence.
- Strong Airline Demand: TD Cowen upgrades Southwest Airlines from Hold to Buy with a target price of $66, anticipating strengthened airline demand in 2026, reflecting the potential for industry recovery.
- AI Software Leader: Rosenblatt initiates coverage of Palantir with a Buy rating and a $150 price target, believing the company holds a unique market position in AI with a sustainable growth trajectory, despite a 33% decline from its peak.
- Optimistic Financial Performance: Bank of America raises Dell's price target to $155, based on its broad product portfolio and AI-related growth potential, expecting higher margins in the coming years, although global economic slowdown poses some risks.
See More
